Caveolin-1 knockout mice show an impaired angiogenic response to exogenous stimuli

American Journal of Pathology

Volumn 162, Issue 6, 2003, Pages 2059-2068

  Woodman, Scott E ^a   Ashton, Anthony W ^a   Schubert, William ^a   Lee, Hyangkyu ^a   Williams, Terence M ^a   Medina, Freddy A ^a   Wyckoff, Jeffrey B ^a   Combs, Terry P ^a   Lisanti, Michael P ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; CAVEOLIN 1; MATRIGEL;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASEMENT MEMBRANE; CAPILLARY; CARCINOGENESIS; CELL ULTRASTRUCTURE; CONTROLLED STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TUMOR VOLUME;

EID: 0038075402     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64337-4     Document Type: Article

References (49)

1. Simionescu N, Simionsecu M: The cardiovascular system. Histology: Cell and Tissue Biology Edited by L Weiss. New York, Elsevier Biomedical, 1983, pp 371-433
2. Simionescu N: Cellular aspects of transcapillary exchange. Physiol Rev 1983, 63:1536-1560
3. Razani B, Woodman SE, Lisanti MP: Caveolae: from cell biology to animal physiology. Pharmacol Rev 2002, 54:431-467
4. Razani B, Lisanti MP: Caveolin-deficient mice: insights into caveolar function and human disease. J Clin Invest 2001, 108:1553-1561
5. Galbiati F, Razani B, Lisanti MP: Emerging themes in lipid rafts and caveolae. Cell 2001, 106:403-411
6. Schubert W, Frank PG, Woodman SE, Hyogo H, Cohen DE, Chow CW, Lisanti MP: Microvascular hyper-permeability in caveolin-1 (-/-) knock-out mice: treatment with a specific NOS inhibitor, L-NAME, restores normal microvascular permeability in Cav-1 null mice. J Biol Chem 2002, 277:40091-40098
7. Razani B, Engelman JA, Wang XB, Schubert W, Zhang XL, Marks CB, Macaluso F, Russell RG, Li M, Pestell RG, Di Vizio D, Hou Jr H, Kneitz B, Lagaud G, Christ GJ, Edelmann W, Lisanti MP: Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J Biol Chem 2001, 276:38121-38138
8. Drab M, Verkade P, Elger M, Kasper M, Lohn M, Lauterbach B, Menne J, Lindschau C, Mende F, Luft FC, Schedl A, Haller H, Kurzchalia TV: Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 2001, 293:2449-2452
9. Conway EM, Collen D, Carmeliet P: Molecular mechanisms of blood vessel growth. Cardiovasc Res 2001, 49:507-521
10. Esser S, Wolburg K, Wolburg H, Breier G, Kurzchalia T, Risau W: Vascular endothelial growth factor induces endothelial fenestrations in vitro. J Cell Biol 1998, 140:947-959
11. Liu J, Wang XB, Park DS, Lisanti MP: Caveolin-1 expression enhances endothelial capillary tubule formation. J Biol Chem 2002, 277:10661-10668
12. Griffoni C, Spisni E, Santi S, Riccio M, Guarnieri T, Tomasi V: Knockdown of caveolin-1 by antisense oligonucleotides impairs angiogenesis in vitro and in vivo. Biochem Biophys Res Commun 2000, 276:756-761
13. Koleske AJ, Baltimore D, Lisanti MP: Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 1995, 92:1381-1385
14. Razani B, Altschuler Y, Zhu L, Pestell RG, Mostov KE, Lisanti MP: Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry 2000, 39:13916-13924
15. Park DS, Lee H, Frank PG, Razani B, Nguyen AV, Parlow AF, Russell RG, Hulit J, Pestell RG, Lisanti MP: Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyper-activation of the Jak-2/STAT5a signaling cascade. Mol Biol Cell 2002, 13:3416-3430
16. Lee H, Park DS, Razani B, Russell RG, Pestell RG, Lisanti MP: Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: Cav-1 (P132L) behaves in a dominant-negative fashion and Cav-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am J Pathol 2002, 161:1357-1369
17. Razani B, Wang XB, Engelman JA, Battista M, Lagaud G, Zhang XL, Kneitz B, Hou Jr H, Christ GJ, Edelmann W, Lisanti MP: Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol Cell Biol 2002, 22:2329-2344
18. Bikfalvi A, Klein S, Pintucci G, Rifkin DB: Biological roles of fibroblast growth factor-2. Endocr Rev 1997, 18:26-45
19. Kawaguchi N, Toriyama K, Nicodemou-Lena E, Inou K, Torii S, Kitagawa Y: De novo adipogenesis in mice at the site of injection of basement membrane and basic fibroblast growth factor. Proc Natl Acad Sci USA 1998, 95:1062-1066
20. Straume O, Akslen LA: Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrn-A1/EphA2 on melanoma progression. Am J Pathol 2002, 160:1009-1019
21. Compagni A, Wilgenbus P, Impagnatiello MA, Cotten M, Christofori G: Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res 2000, 60:7163-7169
22. Franco S, Segura I, Riese HH, Blasco MA: Decreased B16F10 melanoma growth and impaired vascularization in telomerase-deficient mice with critically short telomeres. Cancer Res 2002, 62:552-559
23. Galbiati F, Volonté, D., Engelman JA, Watanabe G, Burk R, Pestell R, Lisanti MP: Targeted down-regulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J 1998, 17:6633-6648
24. Carmeliet P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395
25. Feng D, Nagy JA, Pyne K, Hammel I, Dvorak HF, Dvorak AM: Pathways of macromolecular extravasation across microvascular endothelium in response to VPF/VEGF and other vasoactive mediators. Microcirculation 1999, 6:23-44
26. Dvorak AM, Feng D: The vesiculo-vacuolar organelle (VVO). A new endothelial cell permeability organelle. J Histochem Cytochem 2001, 49:419-432
27. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039
28. Vasile E, Qu H, Dvorak HF, Dvorak AM: Caveolae and vesiculovacuolar organelles in bovine capillary endothelial cells cultured with VPF/VEGF on floating Matrigel-collagen gels. J Histochem Cytochem 1999, 47:159-167
29. Papapetropoulos A, Garcia-Cardena G, Madri JA, Sessa WC: Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J Clin Invest 1997, 100:3131-3139
30. Ziche M, Morbidelli L, Choudhuri R, Zhang HT, Donnini S, Granger HJ, Bicknell R: Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997, 99:2625-2634
31. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA: Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995, 270:1500-1502
32. Labrecque L, Royal I, Surprenant DS, Patterson C, Gingras D, Beliveau R: Regulation of vascular endothelial growth factor receptor-2 activity by caveolin-1 and plasma membrane cholesterol. Mol Biol Cell 2003, 14:334-347
33. Eliceiri BP: Integrin and growth factor receptor crosstalk. Circ Res 2001, 89:1104-1110
34. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA: Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164
35. Brooks PC, Clark RA, Cheresh DA: Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571
36. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA: Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96:1815-1822
37. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM: Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002, 8:27-34
38. Wary KK, Mariott, IA, Zurzolo C, Giancotti FG: A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 1998, 94:625-634
39. Mettouchi A, Klein S, Guo W, Lopez-Lago M, Lemichez E, Westwick JK, Giancotti FG: Integrin-specific activation of Rac controls progression through the G(1) phase of the cell cycle. Mol Cell 2001, 8:115-127
40. Preissner KT, Kanse SM, May AE: Urokinase receptor: a molecular organizer in cellular communication. Curr Opin Cell Biol 2000, 12:621-628
41. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA: A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J Cell Biol 1999, 144:1285-1294
42. Presta M, Moscatelli D, Joseph-Silverstein J, Rifkin DB: Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol Cell Biol 1986, 6:4060-4066
43. Gualandris A, Presta M: Transcriptional and posttranscriptional regulation of urokinase-type plasminogen activator expression in endothelial cells by basic fibroblast growth factor. J Cell Physiol 1995, 162:400-409
44. Liu G, Eskin SG, Mikos AG: Integrin alpha(v)beta(3) is involved in stimulated migration of vascular adventitial fibroblasts by basic fibroblast growth factor but not platelet-derived growth factor. J Cell Biochem 2001, 83:129-135
45. Guo Y, Higazi AA, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kwaan H, Mazar AP, Rabbani SA: A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. EMBO J 2000, 14:1400-1410
46. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM: Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998, 4:923-928
47. Carmeliet P, Jain RK: Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257
48. Capozza F, Williams TM, Schubert W, McClain S. Bouzahzah B, Sotgia F, Lisanti MP: Absence of caveolin-1 sensitizes mouse skin to carcinogen-induced epidermal hyperplasia and tumor formation. Am J Pathol 2003, 162:2029-2039
49. Williams TM, Cheung MWC, Park DS, Razani B, Cohen AW, Muller WJ, Di Vizio D, Chopra NG, Pestell RG, Lisanti MP: Loss of caveolin-1 gene expression accelerates the development of dysplastic mammary lesions in tumor-prone transgenic mice. Mol Biol Cell 2003, 14:1027-1042